#USA #San Diego #John Theurer Cancer Center #ASH Annual Meeting #Hematologic Oncology

Innovative Research from John Theurer Cancer Center at ASH

Researchers from Hackensack Meridian Health's John Theurer Cancer Center (JTCC) actively participated in the 66th Annual Meeting of the American Society of Hematology (ASH) held in San Diego, California, from December 7-10, 2024. This prestigious gathering is a significant platform for sharing cutting-edge advancements in the field of hematologic oncology.

Dr. Andre Goy, chairman and executive director of JTCC, shared insights into the center's reputation for excellence in treating blood cancers, emphasizing the promising developments in treatment options that have the potential to outperform traditional therapies. With a focus not only on advancements in treatment but also on how these innovations can benefit various demographics of patients, JTCC showcased a wide array of pioneering research.

The initiatives presented at ASH included over 70 abstracts co-authored by JTCC researchers, reflecting a diverse range of topics in hematologic cancers. These ranged from leukemia and lymphoma studies to pioneering approaches in bone marrow transplantation and pediatric cancers.

Exploring Key Areas of Research

Some highlighted studies included:

• - Bone Marrow Transplantation Research: Examining how the enforced expression of mitochondrial calcium uniporter in donor T cells may halt graft-versus-host disease (GVHD) progression. This innovative approach sheds light on how cellular interactions can be better regulated to enhance transplant outcomes.
• - Hematologic Oncology Breakthroughs: Findings indicated that lymphodepletion with fludarabine and cyclophosphamide may yield higher complete response rates prior to CAR T therapy as compared to bendamustine, signifying a crucial leap in pre-treatment strategies to enhance patient response.
• - Safety and Efficacy in Novel Therapies: Research on KT-333, a targeted protein degrader of STAT3, showcased its potential safety and efficacy profile in patients with relapsed or refractory lymphomas and leukemias, paving the way for future therapeutic applications.

Pediatric Cancer Innovations

There was also a notable focus on pediatric cancers, with JTCC researchers presenting updates on Lovotibeglogene autotemcel (Lovo-cel) trials aimed at treating sickle cell disease. The trials underscored early predictors of therapeutic response, offering hope for tailored treatments in the pediatric population.

A Legacy of Comprehensive Cancer Care

The John Theurer Cancer Center at Hackensack University Medical Center is recognized as one of the leading cancer care facilities in the nation by U.S. News & World Report. As a research partner with Georgetown's Lombardi Comprehensive Cancer Center, JTCC leads the way in innovative cancer treatment, care management, and survivor support. Each year, countless patients from the New Jersey/New York metropolitan area trust JTCC, attracted by its team of specialized professionals committed to delivering advanced cancer care.

In recent expansions, JTCC has extended its reach to Jersey Shore University Medical Center, broadening access to its world-class services to residents in southern New Jersey and parts of Pennsylvania. Through dedicated efforts, JTCC continues to advance the mission of providing comprehensive, compassionate, and forward-thinking cancer care to all.

For more information about their groundbreaking research and treatment options, please visit John Theurer Cancer Center.